In addition, GLP-1-based therapies have also been recommended as supplemental treatment to metformin administration when HbA1c levels failed be controlled below 7.0% with monotherapy [18], and a fixed-ratio combination of insulin degludec and liraglutide has been implemented as a therapy for T2DM [19], while another combination preparation of insulin glargine and lixisenatide is in clinical development. Here, GCG is linked to type 2 diabetes mellitus.